(Q35104263)

English

Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

phase III clinical trial

0 references

author name string

T Lucas

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

R Astorga

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

1 September 2006

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Clinical Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

65

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

320-326

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

9 July 2018

Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

9 July 2018

Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

9 July 2018

Primary medical therapy for acromegaly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

9 July 2018

Somatostatin receptor subtypes: targeting functional and therapeutic specificity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

9 July 2018

Somatuline Autogel: an extended release lanreotide formulation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

9 July 2018

Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

9 July 2018

Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

9 July 2018

Current therapy for acromegaly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

9 July 2018

Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

9 July 2018

An audit of outcome of treatment in acromegaly.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

9 July 2018

Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

9 July 2018

The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

9 July 2018

Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02595.X

21 January 2018

Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02595.X

21 January 2018

Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02595.X

21 January 2018

Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02595.X

21 January 2018

The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02595.X

21 January 2018

Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02595.X

21 January 2018

Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02595.X

21 January 2018

Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02595.X

21 January 2018

Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02595.X

21 January 2018

Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02595.X

21 January 2018

One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02595.X

21 January 2018

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1618957

27 September 2018

Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/16918950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide

1 reference

https://pubmed.ncbi.nlm.nih.gov/16918950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determinants of clinical outcome and survival in acromegaly

1 reference

https://pubmed.ncbi.nlm.nih.gov/16918950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16918950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/16918950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency

1 reference

https://pubmed.ncbi.nlm.nih.gov/16918950

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2265.2006.02595.X

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35104263&oldid=1995002668"